Page last updated: 2024-08-24

ranolazine and No-Reflow Phenomenon

ranolazine has been researched along with No-Reflow Phenomenon in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hale, SL; Kloner, RA	1

Other Studies

1 other study(ies) available for ranolazine and No-Reflow Phenomenon

Article	Year
The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:3 Topics: Acetanilides; Animals; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Disease Models, Animal; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Piperazines; Rabbits; Ranolazine	2008

Article

Year

The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit.

Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:3

Topics: Acetanilides; Animals; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Disease Models, Animal; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Piperazines; Rabbits; Ranolazine

2008